October 14, 2019 / 5:19 AM / a month ago

BRIEF-Roche Says Phase 3 Study Shows Mabthera/Rituxan Superior To Mycophenolate Mofetil In Patients With Pemphigus Vulgaris

Oct 14 (Reuters) - Roche Holding AG:

* PHASE III PEMPHIX STUDY SHOWS ROCHE’S MABTHERA/RITUXAN (RITUXIMAB) SUPERIOR TO MYCOPHENOLATE MOFETIL IN PATIENTS WITH PEMPHIGUS VULGARIS

* 40% OF PATIENTS WITH PEMPHIGUS VULGARIS (PV) ACHIEVED SUSTAINED COMPLETE REMISSION, WITHOUT USE OF STEROIDS FOR 16 WEEKS OR MORE, WHEN TREATED WITH MABTHERA/RITUXAN COMPARED TO 9.5% OF PATIENTS ON MYCOPHENOLATE MOFETIL

* STUDY REINFORCES EFFICACY AND SAFETY OF MABTHERA/RITUXAN FOR TREATMENT OF PV, A RARE AUTOIMMUNE CONDITION CHARACTERISED BY BLISTERING OF SKIN AND MUCOUS MEMBRANES

* FULL DATA OF 52-WEEK TREATMENT PERIOD PRESENTED AT 28TH CONGRESS OF EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (EADV) IN MADRID Source text for Eikon: [tinyurl.com/y59dzkkg] Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below